Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Sinclair
Harvard Medical School, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cohbar, Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Sinclair serves on the scientific advisory board of Cohbar and has received stock as payment for his services. This study proposes an integrated, multidisciplinary approach to find, validate and characterize an estimated 4000-5000 new peptide-coding genes using a new technology platform and which will provide a more complete roadmap for biology and medicine. CohBar’s mission is to treat age-related diseases and extend healthy life spans through the discovery, optimization and development of novel mitochondrial-derived peptides into clinically relevant and commercially successful mitochrondria based therapeutics. Cohbar may be interested in collaborating on the research and the outcomes of this research could positively benefit Cohbar.
Uncovering the Human Secretome
PROJECT NARRATIVE There has been a rapid expansion in the use of peptide hormones as drugs over the last decade, yet new research indicates that more than 90% of all hormones in the body (encoded by an additional 5% of the human genome) remain to be discovered. As a result, terabytes of data are discarded each week and innumerable opportunities for biological discovery are missed because, according to our findings, the majority of genes below ~300 base pairs are missing from the annotated human genome. We propose an integrated, multi- disciplinary approach to find, validate and characterize an estimated 4000-5000 new peptide-coding genes using a pioneering technology platform that combines breakthroughs in math, custom-built computer hardware and software, and wet-lab approaches, providing a far more complete roadmap for biology and medicine in the 21st century.
Filed on November 06, 2017.
Tell us what you know about David Sinclair's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Sinclair filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | >$600,000 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences | $250,000 - $299,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Senolytic Therapeutics | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | GlaxoSmithKline | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Ovscience | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Ovscience | $40,000 - $59,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | $10,000 - $19,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | OvaScience | $5,000 - $9,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | GlaxoSmithKline | $5,000 - $9,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jumpstart Fertility (wholly owned subsidiary operated by Life) | $0 - $4,999 |
| David Sinclair | Harvard Medical School | Conflict of Interest | EdenRoc Sciences (parent company of Metro International Biotech and Liberty Biosecurity) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Iduna Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Jupiter Orphan Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Liberty Biosecurity (wholly owned and operated subsidiary of EdenRoc Sciences) and EdenRoc Sciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Liberty Biosecurity (wholly owned and operated subsidiary of EdenRoc Sciences) and EdenRoc Sciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | EdenRoc Science | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jumpstart Fertility (wholly owned subsidiary operated by Life) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Spotlight Biosciences Inc. | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Jumpstart Fertility (a subsidiary of Life Biosciences) | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Senolytic Therapeutics | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Metrobiotech East, LLC | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | MetroBiotech Midatlantic, LLC | Value cannot be readily determined |
| David Sinclair | Harvard Medical School | Conflict of Interest | Life Biosciences (parent company) and Jupiter Orphan (wholly owned subsidiary operated by Life) | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.